Figure 2.

Antitumor activity of neratinib. A, Swimmer Plot of time to progression (TTP) for patients with HER2-activating mutations. Co-occurring mutations in TP53, CDH1, and PIK3CA by tumor DNA sequencing are indicated. B, Percentage change in target lesion at best response compared with baseline. Patients with measurable diseases are included. C, Representative CT images of a patient on study. Sixty-four-year old woman (Pt 9) with ER⁺/HER2⁻ metastatic breast cancer, HER2 L755S, prior disease progression on fulvestrant, and exemestane plus everolimus in the metastatic setting, achieved a partial response on neratinib. D, ctDNA HER2 mutation variant allele frequency in response to neratinib. HER2 mutation VAFs at baseline, 4 weeks, and progression are plotted for individual patients (n = 11).